使用纵向秩和检验的多变量纵向试验的效能与样本量计算
该研究针对阿尔茨海默病和帕金森病等具有多变量纵向结局的试验,为纵向秩和检验(LRST)开发了效能与样本量估计方法,整合理论推导、渐近性质与大样本条件下的实用估计技术,数值模拟验证了方法准确性,并在AD和PD临床试验中展示了实际意义。
要点
- LRST无需多重性校正即可评估多个纵向终点的全局治疗效应。
- 研究建立了LRST专用的效能与样本量估计框架,并经数值模拟验证。
- 该方法在阿尔茨海默病和帕金森病临床试验中具有实际应用价值。
核心结论
- 所提出的LRST效能与样本量估计框架有助于设计高效、具有足够效能的试验,推动对具有多变量纵向结局的复杂疾病治疗的评价。
研究设计与样本
- 方法学研究,整合理论推导、渐近性质与大样本条件下的实用估计技术,并通过数值模拟验证所提方法。
- 将所提方法应用于阿尔茨海默病(AD)和帕金森病(PD)临床试验以展示实际意义。
主要发现
- 数值模拟表明所提出的效能与样本量估计方法具有准确性。
- 在AD和PD临床试验中的应用显示了该框架的实际意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurodegenerative diseases such as Alzheimer's and Parkinson's often exhibit complex, multivariate longitudinal outcomes that require advanced statistical methods to comprehensively evaluate treatment efficacy. The Longitudinal Rank Sum Test (LRST) offers a nonparametric framework to assess global treatment effects across multiple longitudinal endpoints without requiring multiplicity corrections. This study develops a robust methodology for power and sample size estimation specific to the LRST, integrating theoretical derivations, asymptotic properties, and practical estimation techniques under large sample conditions. Validation through numerical simulations demonstrates the accuracy of the proposed methods, while real-world applications to clinical trials in Alzheimer's disease (AD) and Parkinson's disease (PD) highlight their practical significance. This framework facilitates the design of efficient, well-powered trials, advancing the evaluation of treatments for complex diseases with multivariate longitudinal outcomes.
引用
- Ghosh D, Xu X, Luo S, et al. Power and Sample Size Calculation for Multivariate Longitudinal Trials Using the Longitudinal Rank Sum Test. Stat Med. 2025. PMID: 40947402. doi:10.1002/sim.70261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。